AstraZeneca acquires neuroscience assets from Link Medicine

Friday, July 13, 2012 03:20 PM

AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, a privately held biopharmaceutical company based in Massachusetts. Link Medicine has focused its R&D efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins, and has been developing potential new treatments for a range of neurodegenerative diseases.

AstraZeneca acquired multiple small molecule assets in clinical and preclinical stages that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease, both of which are characterized by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.

The agreement is the third for AstraZeneca's new neuroscience Innovative Medicines Unit, established earlier this year. Under this new model, AstraZeneca is continuing to invest in neuroscience discovery research and early development for small and large molecules by tapping into the best available external science.

AstraZeneca will make specified upfront and milestone payments and will assume all of the program's R&D activities.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs